跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BYDUREON - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BYDUREON
Authorized
STANDARD
BYDUREON
astrazeneca canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
632cc961c04469ea
Company
astrazeneca canada inc
Type
Standard
Approval Details
Approval Id
632cc961c04469ea
Drug Approval Canada Name
BYDUREON
Product Name
BYDUREON
Status
Cancelled Post Market
Status Date
2022-04-01
Original Market Date
2016-02-16
Din
02448610
Drug Class
Human
Dosage Form
Kit , Powder For Suspension, Sustained-Release
Route Of Administration
Subcutaneous
Schedule
Prescription
Ahfs
68:20.06
Atc Original
A10BJ01 EXENATIDE
Atc Name
a 10 bj 01
Aig Number
0152872002
Company Name
astrazeneca canada inc
Company Address
1004 Middlegate Road, Suite 5000, Mississauga, Ontario, Canada, L4Y 1M4
Active Ingredients
EXENATIDE
2 MG / DOSE
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
632cc961c04469ea
Type
Standard
Back to Health Canada Approvals